Mustafa Erman

8.7k total citations
117 papers, 1.0k citations indexed

About

Mustafa Erman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Mustafa Erman has authored 117 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 47 papers in Pulmonary and Respiratory Medicine and 18 papers in Epidemiology. Recurrent topics in Mustafa Erman's work include Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Treatments and Mutations (15 papers) and Inflammatory Biomarkers in Disease Prognosis (15 papers). Mustafa Erman is often cited by papers focused on Cancer Immunotherapy and Biomarkers (33 papers), Lung Cancer Treatments and Mutations (15 papers) and Inflammatory Biomarkers in Disease Prognosis (15 papers). Mustafa Erman collaborates with scholars based in Türkiye, United States and South Korea. Mustafa Erman's co-authors include Sercan Aksoy, İ. Çelik, Saadettin Kılıçkap, İhsan Ertenli, Meral Çalgünerı, Sedat Kiraz, Hüseyin Abalı, İbrahim C. Haznedaroğlu, Deniz Can Güven and Hakan Harputluoğlu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Mustafa Erman

96 papers receiving 985 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mustafa Erman 401 271 156 148 124 117 1.0k
Canan Akyüz 250 0.6× 289 1.1× 66 0.4× 124 0.8× 255 2.1× 96 1.3k
Kyung Duk Park 199 0.5× 185 0.7× 76 0.5× 57 0.4× 209 1.7× 103 1.2k
Girish Chinnaswamy 184 0.5× 296 1.1× 32 0.2× 93 0.6× 234 1.9× 124 1.0k
Arijit Ganguli 126 0.3× 196 0.7× 167 1.1× 439 3.0× 66 0.5× 90 1.4k
Furqan Shaikh 134 0.3× 257 0.9× 67 0.4× 51 0.3× 179 1.4× 64 1.2k
Ömer Dızdar 748 1.9× 307 1.1× 22 0.1× 54 0.4× 242 2.0× 141 1.5k
Debora Formisano 183 0.5× 386 1.4× 35 0.2× 111 0.8× 96 0.8× 36 1.3k
Christine Mauz‐Körholz 369 0.9× 317 1.2× 25 0.2× 62 0.4× 158 1.3× 87 1.5k
Ronny Nienhold 250 0.6× 180 0.7× 25 0.2× 173 1.2× 436 3.5× 19 1.8k
Noha Abdel‐Wahab 1.6k 4.1× 441 1.6× 33 0.2× 194 1.3× 234 1.9× 60 2.3k

Countries citing papers authored by Mustafa Erman

Since Specialization
Citations

This map shows the geographic impact of Mustafa Erman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mustafa Erman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mustafa Erman more than expected).

Fields of papers citing papers by Mustafa Erman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mustafa Erman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mustafa Erman. The network helps show where Mustafa Erman may publish in the future.

Co-authorship network of co-authors of Mustafa Erman

This figure shows the co-authorship network connecting the top 25 collaborators of Mustafa Erman. A scholar is included among the top collaborators of Mustafa Erman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mustafa Erman. Mustafa Erman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).
2.
3.
Erman, Mustafa, et al.. (2025). Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina. 61(3). 490–490. 1 indexed citations
4.
Güven, Deniz Can, et al.. (2025). Comparative Analysis of Prognostic Potential of Pretreatment Blood-Based Biomarkers in Metastatic Bladder Cancer: Modified Glasgow Prognostic Score. Journal of Clinical Medicine. 14(6). 1954–1954. 1 indexed citations
5.
Şahin, Taha Koray, Deniz Can Güven, Zafer Arık, et al.. (2025). The association between blood sodium levels and survival in patients treated with immune checkpoint inhibitors. Expert Review of Molecular Diagnostics. 25(4). 129–137.
6.
7.
Demir, Tarık, Murat Araz, Mehmet Zahid Koçak, et al.. (2024). Efficacy of systemic treatments in patients with metastatic lung invasive mucinous adenocarcinoma.. Journal of Clinical Oncology. 42(16_suppl). e20609–e20609.
8.
Arslan, Çağatay, Fatih Selçukbırıcık, Ömer Fatih Ölmez, et al.. (2024). Association Between Baseline and Changes in Early Neutrophil-to-Lymphocyte Ratio on Survival in Patients with Metastatic Bladder Carcinoma Treated with Immunotherapy. Medicina. 60(12). 2103–2103.
9.
Lara, Primo N., Luis J. Villanueva-Rivera, Carolina Ibáñez, et al.. (2024). A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302). BMC Cancer. 23(S1). 1253–1253. 11 indexed citations
10.
11.
Güven, Deniz Can, Kaan Helvacı, Erdinç Nayır, et al.. (2023). The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study. Cancer Medicine. 13(1). e6869–e6869. 1 indexed citations
12.
Yıldırım, Hasan Çağrı, Deniz Can Güven, Oktay Halit Aktepe, et al.. (2022). Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease. Journal of Clinical Medicine. 11(17). 5171–5171. 5 indexed citations
13.
Güven, Deniz Can, Taha Koray Şahin, Enes Erul, et al.. (2022). The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy. Journal of Clinical Medicine. 11(15). 4523–4523. 22 indexed citations
14.
Levy, Benjamin, Fabrice Barlési, Luis Paz‐Ares, et al.. (2022). Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO). Lung Cancer. 166. 107–113. 6 indexed citations
15.
16.
Aktepe, Oktay Halit, et al.. (2021). Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma. SHILAP Revista de lepidopterología. 47(2). 113–119. 6 indexed citations
17.
Jabbour, Salma K., Baerin Houghton, Andrew Robinson, et al.. (2020). Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867. International Journal of Radiation Oncology*Biology*Physics. 108(3). e135–e136.
18.
Akın, Serkan, et al.. (2016). Vaccination perception and attitudes among patients with cancer receiving chemotherapy. Annals of Oncology. 27. vi514–vi514. 2 indexed citations
19.
Hayran, Mutlu, Deniz Yüce, Ece Esin, et al.. (2015). Quality of Life Domains Associated With Readmission. Value in Health. 18(3). A211–A212. 1 indexed citations
20.
Arslan, Çağatay, Saadettin Kılıçkap, Didem Şener Dede, et al.. (2011). 65 Yaş ve üzeri popülasyonda kanser sıklığının dağılımı: Hacettepe Üniversitesi Hastaneleri kanser kayıt sistemi sonuçları. The Turkish Journal of Geriatrics. 14(3). 187–192.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Canan Akyüz Breakdown of academic impact, for papers by Kyung Duk Park Breakdown of academic impact, for papers by Girish Chinnaswamy Breakdown of academic impact, for papers by Arijit Ganguli Breakdown of academic impact, for papers by Furqan Shaikh Breakdown of academic impact, for papers by Ömer Dızdar Breakdown of academic impact, for papers by Debora Formisano Breakdown of academic impact, for papers by Christine Mauz‐Körholz Breakdown of academic impact, for papers by Ronny Nienhold Breakdown of academic impact, for papers by Noha Abdel‐Wahab
Rankless by CCL
2026